Guangxitoxin
Guangxitoxin, also known as GxTX, is a peptide toxin found in the venom of the tarantula Chilobrachys guangxiensis.
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Guangxitoxin, also known as GxTX, is a peptide toxin found in the venom of the tarantula Chilobrachys guangxiensis. It primarily inhibits outward voltage-gated K v 2.1 potassium channel currents, which are prominently expressed in pancreatic β-cells, thus increasing insulin secretion.
Sources
Guangxitoxin is found in the venom of the tarantula Chilobrachys guangxiensis, which lives mainly in Guangxi province of southern China.
Subtypes
Guangxitoxin consists of multiple subtypes, including GxTX-1D, GxTX-1E and GxTX-2. GxTX-2 shows sequence similarities with Hanatoxin (HaTX), Stromatoxin-1 (ScTx1), and Scodra griseipes toxin (SGTx) peptides. GxTX-1 shows sequence similarities with Jingzhaotoxin-III (JZTX-III), Grammostola spatulata mechanotoxin-4 (GsMTx-4), and Voltage-sensor toxin-1 (VSTX1) peptides.
GxTX-1 consists of two variants, GxTX-1D and GxTX-1E, of which GxTX-1E is a more potent inhibitor of K v 2.1.
Sequence
GxTX-1D and GxTX-1E consist of 36 amino acids, differing only a single amino acid at the NH 2 -terminal, aspartate or glutamate, respectively: Asp/Glu-Gly-Glu-Cys-Gly-Gly-Phe-Trp-Trp-Lys-Cys-Gly-Ser-Gly-Lys-Pro-Ala-Cys-Cys-Pro-Lys-Tyr-Val-Cys-Ser-Pro-Lys-Trp-Gly-Leu-Cys-Asn-Phe-Pro-Met-Pro GxTX-2 consists of 33 amino acids, which has only 9 identical amino acids in corresponding sequence compared to GxTX-1D and GxTX-1E: Glu-Cys-Arg-Lys-Met-Phe-Gly-Gly-Cys-Ser-Val-Asp-Ser-Asp-Cys-Cys-Ala-His-Leu-Gly-Cys-Lys-Pro-Thr-Leu-Lys-Tyr-Cys-Ala-Trp-Asp-Gly-Thr
Target
GxTX-1E inhibits voltage-gated K v 2.1 channels by modifying its voltage-dependent gating,. mutations in the S3b-S4 paddle motif of the voltage-sensing domain of K v 2.1 reduce affinity for tarantula toxins. Two other voltage-gated potassium channels inhibited by GxTX-1 are the K v 2.2 and K v 4.3 channels. K v 2.2 is located predominantly in δ-cells of primate islets.
K v 4.3 is mainly of importance in the heart. The K v 2.1 channel is predominantly expressed in pancreatic β-cells and in the central nervous system. In pancreatic β-cells, K v 2.1 comprises 60% of the currents mediated by K v channels.
Furthermore, the K v 2.1 channel shows similar biophysical properties to the delayed rectifier K + current (I DR ) of the β-cells. This makes GxTX appropriate to study the physiological role of the aforementioned current as it inhibits 90% of the β-cell I DR . The I DR is thought to play an important role in repolarization of action potentials.
Both the K v 2.2 and K v 4.3 channels are believed not to contribute significantly to the β-cell I DR . GxTX-1E has no effect on voltage-gated Na + or Ca 2+ channels.
Mode of action
Inhibition of K v 2.1 by GxTX-1E causes a shift in voltage-dependency of activation toward more positive potentials of almost 100 mV. Moreover, GxTX-1E also exhibits properties of decreasing the velocity of hK v 2.1 channel opening and increasing the velocity of K v 2.1 channel closing approximately sixfold.
By inhibiting K v 2.1 potassium channels, GxTX-1E boosts action potentials of pancreatic β-cells causing mainly increased glucose-stimulated intracellular calcium oscillations which in turn intensifies glucose-stimulated insulin secretion. How GxTX-1E can generate distinctive calcium oscillations in different cells remains unclear (broader oscillations, increased frequency or restoration of oscillations), however, the specificity of GxTX-1E points in the direction of I DR inhibition causing these effects.
Notably, GxTX-1E stimulated insulin secretion is specifically glucose-dependent, considering that I DR is only active above -20mV membrane potentials which is only seen in raised glucose levels.
Therapeutic use
Unlike K ATP channel blockers, GxTX-1 primarily blocks I DR and demonstrates a potential target for future drugs in diabetes mellitus type 2 treatment, since a blockade of I DR should not provoke hypoglycaemia.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1350724629 under CC BY-SA 4.0; modifications have been made.